A detailed history of Bourne Lent Asset Management Inc transactions in Amgen Inc stock. As of the latest transaction made, Bourne Lent Asset Management Inc holds 9,770 shares of AMGN stock, worth $2.57 Million. This represents 1.19% of its overall portfolio holdings.

Number of Shares
9,770
Previous 9,745 0.26%
Holding current value
$2.57 Million
Previous $3.04 Million 3.38%
% of portfolio
1.19%
Previous 1.17%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$309.38 - $337.38 $7,734 - $8,434
25 Added 0.26%
9,770 $3.15 Million
Q2 2024

Aug 01, 2024

SELL
$262.75 - $319.31 $19,706 - $23,948
-75 Reduced 0.76%
9,745 $3.04 Million
Q1 2024

Apr 12, 2024

BUY
$268.87 - $324.56 $26,887 - $32,456
100 Added 1.03%
9,820 $2.79 Million
Q4 2023

Jan 19, 2024

BUY
$255.7 - $288.46 $86,938 - $98,076
340 Added 3.62%
9,720 $2.8 Million
Q2 2023

Jul 17, 2023

SELL
$214.27 - $253.37 $74,994 - $88,679
-350 Reduced 3.6%
9,380 $2.08 Million
Q4 2022

Jan 23, 2023

SELL
$229.03 - $291.01 $62,296 - $79,154
-272 Reduced 2.72%
9,730 $0
Q1 2022

Apr 26, 2022

BUY
$219.27 - $242.57 $87,708 - $97,028
400 Added 4.17%
10,002 $2.42 Million
Q4 2021

Jan 20, 2022

BUY
$198.88 - $227.6 $887,999 - $1.02 Million
4,465 Added 86.92%
9,602 $2.16 Million
Q4 2020

Jan 27, 2021

SELL
$216.38 - $257.67 $43,276 - $51,534
-200 Reduced 3.75%
5,137 $1.18 Million
Q1 2020

Apr 17, 2020

BUY
$182.24 - $241.7 $27,336 - $36,255
150 Added 2.89%
5,337 $1.08 Million
Q4 2019

Jan 24, 2020

BUY
$189.21 - $243.2 $56,763 - $72,960
300 Added 6.14%
5,187 $1.25 Million
Q1 2018

Apr 20, 2018

SELL
$169.43 - $198.0 $74,549 - $87,120
-440 Reduced 8.26%
4,887 $833,000
Q3 2017

Oct 16, 2017

BUY
$167.29 - $191.0 $891,153 - $1.02 Million
5,327
5,327 $993,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Bourne Lent Asset Management Inc Portfolio

Follow Bourne Lent Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bourne Lent Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bourne Lent Asset Management Inc with notifications on news.